Senseonics to Participate in the Cowen Health Care Conference
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans
to participate in the upcoming Cowen Health Care Conference in Boston, MA.
Management is scheduled to present Wednesday, March 13, 2019 at 10:40am ET. Interested parties may access a live and recorded
webcast of the presentation on the “Investor Relations” section of the company’s website at
www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of
transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its
inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The
Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States.
The Eversense® XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe. For more information
on Senseonics, please visit
www.senseonics.com.
Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005955/en/